Do interventions to improve adherence to antiretroviral therapy recognise diversity? A systematic review

被引:3
作者
Wali, Nidhi [1 ]
Renzaho, Andre [1 ]
Wang, Xia [2 ]
Atkins, Bethany [2 ]
Bhattacharya, Debi [2 ]
机构
[1] Western Sydney Univ, Sch Social Sci & Psychol, Sydney, NSW, Australia
[2] Univ East Anglia, Sch Pharm, Norwich NR4 7TJ, Norfolk, England
来源
AIDS CARE-PSYCHOLOGICAL AND SOCIO-MEDICAL ASPECTS OF AIDS/HIV | 2021年 / 33卷 / 11期
关键词
HIV; generalisability; diversity; trial reporting guidelines; transferability; RANDOMIZED CONTROLLED-TRIAL; HIV MEDICATION ADHERENCE; COGNITIVE-BEHAVIORAL THERAPY; SINGLE-TABLET REGIMEN; PATIENT-REPORTED OUTCOMES; INCREASE ADHERENCE; SELF-MANAGEMENT; SUBSTANCE USERS; DRUG-USERS; OPEN-LABEL;
D O I
10.1080/09540121.2020.1811198
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
People living with HIV (PLWH) are often culturally and linguistically diverse populations; these differences are associated with differing barriers to antiretroviral therapy (ART) adherence. Cultural competence measures the extent to which trial design recognises this diversity. This systematic review aimed to determine whether adherence trial participants represent the diversity of PLWH. Randomised Controlled Trials in Organisation for Economic Co-operation and Development countries to improve ART adherence were eligible. We searched MEDLINE, EMBASE, and Cochrane Database of Systematic Reviews. For all included trials, we searched for their development, testing and evaluation studies. We compared trial participant characteristics with nationally reported PLWH data. We appraised trial cultural competence against ten criteria; scoring each criterion as 0, 1 or 2 indicating cultural blindness, pre-competence or competence respectively. For 80 included trials, a further 13 studies presenting development/testing/evaluation data for the included trials were identified. Only one of the 80 included studies reported trial participants representative of the country's population of PLWH. The median (IQ) cultural competence score was 2.5 (1.0, 4.0) out of 20. HIV adherence trial participants are not reflective of the population with HIV, which may be due to limited adoption of culturally competent research methods.
引用
收藏
页码:1379 / 1393
页数:15
相关论文
共 111 条
  • [1] Alsan M, 2017, AIDS, V31, P1765, DOI [10.1097/QAD.0000000000001543, 10.1097/qad.0000000000001543]
  • [2] Developing a directly administered antiretroviral therapy intervention for HIV-infected drug users: Implications for program replication
    Altice, FL
    Mezger, JA
    Hodges, J
    Bruce, RD
    Marinovich, A
    Walton, M
    Springer, SA
    Friedland, GH
    [J]. CLINICAL INFECTIOUS DISEASES, 2004, 38 : S376 - S387
  • [3] ALTICE FL, 2007, CLIN INFECT DIS, V45, P770, DOI DOI 10.1086/521166
  • [4] Correlates and predictors of adherence to highly active antiretroviral therapy: Overview of published literature
    Ammassari, A
    Trotta, MP
    Murri, R
    Castelli, F
    Narciso, P
    Noto, P
    Vecchiet, J
    D'Arminio Monforte, A
    Wu, AW
    Antinori, A
    [J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2002, 31 : S123 - S127
  • [5] A programmable prompting device improves adherence to highly active antiretroviral therapy in HIV-infected subjects with memory impairment
    Andrade, ASA
    McGruder, HF
    Wu, AW
    Celano, SA
    Skolasky, RL
    Selnes, OA
    Huang, IC
    McArthur, JC
    [J]. CLINICAL INFECTIOUS DISEASES, 2005, 41 (06) : 875 - 882
  • [6] [Anonymous], 2017, HIV SURV REP 2016
  • [7] [Anonymous], 2008, END FRAM PREF PRACT
  • [8] [Anonymous], 2007, RES COMMUNITIES GROU
  • [9] Randomized clinical trial of cognitive behavioral stress management on human immunodeficiency virus viral load in gay men treated with highly active antiretroviral therapy
    Antoni, MH
    Carrico, AW
    Durán, RE
    Spitzer, S
    Penedo, F
    Ironson, G
    Fletcher, MA
    Klimas, N
    Schneiderman, N
    [J]. PSYCHOSOMATIC MEDICINE, 2006, 68 (01): : 143 - 151
  • [10] Simplification to single-tablet regimen of elvitegravir, cobicistat, emtricitabine, tenofovir DF from multi-tablet ritonavir-boosted protease inhibitor plus coformulated emtricitabine and tenofovir DF regimens: week 96 results of STRATEGY-PI
    Arribas, Jose R.
    DeJesus, Edwin
    van Lunzen, Jan
    Zurawski, Christine
    Doroana, Manuela
    Towner, William
    Lazzarin, Adriano
    Nelson, Mark
    McColl, Damian
    Andreatta, Kristen
    Swamy, Raji
    Szwarcberg, Javier
    Thai Nguyen
    [J]. HIV CLINICAL TRIALS, 2017, 18 (03): : 118 - 125